NEUROCRINE BIOSCIENCES INC Form 3 March 14, 2019 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION O Washington, D.C. 20549 OMB

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> NEUROCRINE BIOSCIENCES INC	2. Date of Event Requiring Statement (Month/Day/Year) 03/12/2019	3. Issuer Name and Ticker or Tradir Voyager Therapeutics, Inc. [N				
(Last) (First) (Middle)		4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)			
12780 EL CAMINO REAL			r nou(monal/Day, roa)			
(Street)		(Check all applicable)	6. Individual or Joint/Group			
SAN DIEGO, CA 92130		DirectorX10% Owner OfficerOther (give title below) (specify below)	Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned					
1.Title of Security (Instr. 4)	2. Amount of Beneficially ((Instr. 4)		•			
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02) Persons who respond to the collection of						
information cor required to res	tained in this form are not ond unless the form displa DMB control number.	ays a				
Table II Dominative Sec	witing Donoficially Owned (a	a nute colle momente entiene co	www.artible.commities)			

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I)	

OMB APPROVAL

Estimated average burden hours per

Number:

Expires:

response...

3235-0104

January 31,

2005

0.5

Reporting Owners

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
NEUROCRINE BIOSCIENCES INC 12780 EL CAMINO REAL SAN DIEGO, CA 92130	Â	ÂX	Â	Â			
Signatures							
/s/ Darin Lippodlt, Chief Legal Officer Secretary	03/14/2019						
<u>**</u> Signature of Reporting Perso	Date						
Explanation of Responses:							

No securities are beneficially owned

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(Instr. 5)